Methotrexate-induced cutaneous ulceration and necrosis in chronic atopic dermatitis

Malika A. Ladha, MD,a Bryn Edgerton, BSc(Hons),b Jonathan Levy, MD,c Muhammad N. Mahmood, MD,d Alim R. Devani, MD,e Parbeer S. Grewal, MD,e and Vimal H. Prajapati, MDa,e,f,g
Edmonton and Calgary, Alberta, Canada

INTRODUCTION
Methotrexate is a folic acid antagonist used to treat malignant and inflammatory diseases.1 Cutaneous ulceration and necrosis is a rare adverse event. Within dermatology, this phenomenon has occurred almost exclusively in psoriasis.2 We present a case of methotrexate-induced cutaneous ulceration and necrosis in chronic atopic dermatitis.

CLINICAL CASE
A 56-year-old woman presented to the emergency department with fever and generalized skin eruption. Medical history was significant for congestive heart failure treated with furosemide and childhood-onset atopic dermatitis refractory to various topical corticosteroids. One week earlier, another practitioner had prescribed her oral methotrexate for erythroderma secondary to atopic dermatitis. Baseline laboratory investigation results were within normal limits. She misinterpreted the instructions and accidentally consumed 7.5 mg every 12 hours for 7 days (cumulative dosage 105 mg) without folic acid. Physical examination revealed widespread, well-demarcated, irregularly shaped, coalescing, superficial ulcers with overlying necrotic eschars arising within areas of scale and erythema on the trunk and extremities (Fig 1). There were no oral or genital ulcers. Atopic features such as lichenification and palmar hyperlinearity were noted. Scalp and nail abnormalities were not observed. Laboratory investigations demonstrated pancytopenia and neutropenia, but normal liver and renal studies. The clinical differential diagnosis included methotrexate-induced necrotic skin ulceration or herpes simplex virus (HSV) infection.

Full septic evaluation (blood, urine, and skin cultures) plus studies for HSV (direct fluorescent antibody and polymerase chain reaction) were negative. Skin biopsy demonstrated sharply defined areas of epidermal ulceration and necrosis (Fig 2). HSV-induced cytopathic changes were absent and HSV immunohistochemistry was negative. Histopathology thus supported the clinical diagnosis of methotrexate-induced necrotic skin ulceration.

Initial treatment included methotrexate discontinuation, folinic acid administration (10 mg/m2 every 6 hours), wound care, and empirical intravenous acyclovir plus piperacillin-tazobactam. The latter 2 medications were discontinued with recovery of the neutrophil count. Folinic acid and wound care were continued until complete epithelization of the necrotic ulcers, which took approximately 10 days (Fig 3).

DISCUSSION
Methotrexate is a synthetic folic acid analogue with both antiproliferative and anti-inflammatory
properties.¹ It inhibits dihydrofolate reductase to decrease folate, thereby interfering with DNA synthesis and cellular division.¹ The adverse events of methotrexate are classified as follows: type A, dose-dependent; type B, idiosyncratic; type C, resulting from long-term exposure; and type D, delayed even in the context of discontinuation.³ The most common adverse events include fatigue, malaise, nausea, emesis, and anorexia; these are dose-dependent and can be reduced with concurrent administration of folic acid.⁴ Methotrexate can also rarely cause severe, potentially life-threatening adverse events, including hepatotoxicity and myelosuppression.⁴

Skin-related complications are type A and include cutaneous ulceration and necrosis. Within dermatology, this has occurred almost exclusively in the setting of psoriasis.² A potential explanation may be increased cell turnover, making these tissues particularly susceptible to cytocidal effects.² There are only 8 reported cases in nonpsoriatic patients with an underlying primary dermatologic disease, either bullous pemphigoid or mycosis fungoides (Table I).²,⁵-⁸ To our knowledge, this is the first reported case of methotrexate-induced cutaneous ulceration and necrosis in atopic dermatitis. The latter is especially important because methotrexate is frequently used to treat pediatric and adult atopic dermatitis.⁹

Risk factors for cutaneous ulceration and necrosis secondary to methotrexate include alteration in methotrexate regimen (recent institution, high initial dose without folic acid supplementation, or resumption after brief hiatus), concurrent use of medications that impair renal tubular secretion of methotrexate, advanced age (especially ≥ 55 years), concomitant infection, chronic kidney disease or renal insufficiency, hypoalbuminemia, and increased mean cell volume.² Our patient’s risk factors included recent institution of methotrexate, high initial dose of methotrexate without folic acid supplementation, advanced age, and concurrent use of a medication that impairs renal tubular secretion.
Table I. Reports of methotrexate-induced cutaneous or mucosal ulceration and necrosis in patients with nonpsoriatic primary dermatologic conditions

| Author                                      | Age, years | MTX dose/duration                                      | Cause                     | Risk factors                                                                                           | Distribution of MTX-induced ulceration and necrosis | Mucosal involvement with MTX-induced ulceration and necrosis | Treatment (in addition to MTX discontinuation) |
|---------------------------------------------|------------|--------------------------------------------------------|---------------------------|--------------------------------------------------------------------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------------|
| Bullous pemphigoid                          | 76         | 10 mg/wk PO for 4 mo; increased to 10 mg/day PO for preceding wk | Patient error             | Alteration in MTX regimen, concurrent medication that impairs renal secretion, advanced age, concomitant infection (cellulitis), chronic kidney disease | Trunk, upper extremities, lower extremities          | No                                                              | Folinic acid (PO), filgrastim (NS)                  |
| Borda et al                                 | 73         | 10 mg/wk PO for 10 d                                   | NA                        | Advanced age                                                                                           | NS                                                  | No                                                              | Methylprednisolone (IV)                                |
| Delyon et al                                 | 92         | 2.5 mg/d PO, 5 d/wk for 3 wk                           | Patient error             | Advanced age                                                                                           | Oral mucosa (gingiva and soft palate)               | Yes                                                             | Folinic acid (NS)                                   |
| Mycosis fungoides                           | 81         | 10 mg/wk PO for 7 wk                                   | NA                        | Advanced age                                                                                           | Axillae/inguinal regions, buttocks, lower extremities | No                                                              | Nil                                              |
| Breneman et al                              | 78         | 40 mg/wk IV for 3 wk                                   | NA                        | Concurrent medication that impairs renal secretion, advanced age                                      | Scalp, trunk, buttocks, upper extremities, lower extremities | No                                                              | Nil                                              |
|                                            | 77         | 10 mg/wk PO increased to 40 mg/wk PO for 12 wk         | NA                        | Alteration in MTX regimen, advanced age                                                                 | Scalp, face, trunk, buttocks                        | No                                                              | Nil                                              |
|                                            | 67         | 50 mg/wk IV for 6 mo; then increased to 60 mg/wk IV for 4.5 y | Acute renal failure       | Alteration in MTX regimen, advanced age, renal insufficiency (postobstructive acute renal failure)  | Axillary/inguinal regions, gluteal cleft            | No                                                              | Fluid hydration (IV), folate (NS), folinic acid (NS) |
| Mna et al                                   | 57         | 10 mg/wk PO for 3 mo; then increased to 25 mg/wk PO    | NA                        | Alteration in MTX regimen, advanced age                                                                 | Scalp, face, trunk, upper extremities, lower extremities | No                                                              | Nil                                              |

*IV*, Intravenous; *MTX*, methotrexate; *NA*, not available; *NS*, not specified; *PO*, per os.
Clinicians should consider methotrexate-induced cutaneous necrosis and ulceration as a possible adverse event, especially if risk factors are present. High clinical suspicion for this diagnosis should prompt the following management: immediate discontinuation of methotrexate, administration of folinic acid, appropriate wound care, and monitoring of potential laboratory abnormalities, especially if myelosuppression is present.

**CONCLUSION**

Cutaneous ulceration and necrosis is a rare adverse event of methotrexate. Although most often limited to patients with psoriasis, this complication can occur in the setting of atopic dermatitis, as demonstrated by our patient.

**REFERENCES**

1. Costa MP, Ferrari S. Update on antifolate drugs targets. *Curr Drug Targets*. 2001;2(2):135-166.
2. Chen TJ, Chung WH, Chen CB, et al. Methotrexate-induced epidermal necrosis: a case series of 24 patients. *J Am Acad Dermatol*. 2017;77(2):247-255.e2.
3. Del Pozo J, Martínez W, García-Silva J, Almagro M, Peña-Penabad C, Fonseca E. Cutaneous ulceration as a sign of methotrexate toxicity. *Eur J Dermatol*. 2001;11:450-452.
4. Shen S, O’Brien T, Yap LM, Prince HM, McCormack CJ. The use of methotrexate in dermatology: a review. *Australas J Dermatol*. 2012;53(1):1-18.
5. Borda L, Ross A, Villada G, Milikowski C. Acute mucocutaneous methotrexate toxicity with marked tissue eosinophilia. *BMU Case Rep*. 2018;2018. https://doi.org/10.1136/bcr-2017-221489.
6. Delyon J, Ortonne N, Benayoun E, et al. Low-dose methotrexate-induced skin toxicity: keratinocyte dystrophy as a histologic marker. *J Am Acad Dermatol*. 2015;73(3):484-490.
7. Breneman DL, Storer TJ, Breneman JC, Mutasim DF. Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides. *Ther Clin Risk Manag*. 2008;4(5):1135-1141.
8. Mna AB, Souissi A, Halouani S, et al. Methotrexate-induced necrolysis in tumoral-stage mycosis fungoides: a challenging diagnosis. *Dermatol Online J*. 2016;22(1). pii: 13030/qt7m8h9n3.
9. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. *J Am Acad Dermatol*. 2014;71(2):327-349.